Bavarian Nordic A/S (0DPB.IL)

155.77 +1.52 (+0.99%) At close: 05:31PM BST

Bavarian Nordic A/S

Philip Heymans Alle 3
Hellerup 2900
Denmark
45 33 26 83 83
https://www.bavarian-nordic.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,354

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Paul John Chaplin MSc, Ph.D.	CEO & Pres	11.01M	N/A	1967
Mr. Henrik Juuel M.Sc.	CFO & Exec. VP	5.89M	N/A	1965
Mr. Russell Thirsk	Exec. VP & COO	N/A	N/A	1968
Mr. Rolf Sass Sørensen	VP of Investor Relations & Communications	N/A	N/A	N/A
Ms. Anu Helena Kerns	Exec. VP & Chief People Officer	N/A	N/A	1972
Mr. Jean-Christophe May	Exec. VP & Chief Commercial Officer	N/A	N/A	1967
Dr. Laurence De Moerlooze	Exec. VP & Chief Medical Officer	N/A	N/A	1964

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Corporate governance

Bavarian Nordic A/S’s ISS governance QualityScore as of 1 October 2023 is 1. The pillar scores are Audit: 4; Board: 1; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.